Clinical trials
catalyst calendar across sponsors →Studies where SLN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 with posted results
Held by 11 tracked-famous managers (CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., JANE STREET GROUP, LLC, Schonfeld Strategic Advisors LLC, +6 more) · FINRA short interest 3.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Assess SLN124 in Patients With Polycythemia VeraNCT05499013Phase 1: Incidence of treatment-emergent adverse events (AEs)Randomized · Double-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: SLN124, Placebo | Polycythemia Vera | 69 | Sep 2026 | ≤ 42 d | 2025-12-19 |
| Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsNCT05537571results2025-07-01Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SLN360, Placebo | Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a) | 180 | 2024-01-11actual | — | 2025-07-01 |
| Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)NCT04606602Incidence of treatment-emergent adverse eventsRandomized · Double-masked · Prevention | Phase 1 | Completed | Drug: SLN360, Placebo | Hyperlipidemias, Dyslipidemias, Elevated Lp(a) | 70 | 2023-08-23actual | — | 2024-08-12 |
| A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic SyndromeNCT04718844Incidence of treatment-emergent adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SLN124, Placebo | Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome | 44 | 2023-05-23actual | — | 2024-01-03 |
| Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124NCT04176653# of participants with all AEs as assessed by CTCAE V4.0 included injection site reaction, will be measured from baseline to post dose follow upRandomized · Double-masked · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Study stopped prior to subject administered first dose, due to COVID-19 | Drug: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome | 0 | 2021-09-30 | — | 2020-04-27 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy VolunteersNCT04559971Incidence of treatment-emergent adverse eventsRandomized · Double-masked · Treatment | Early Phase 1 | Completed | Drug: SLN124, Placebo | Healthy Volunteers | 24 | 2021-03-23actual | — | 2023-04-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19